Feature | Total Group | Positive Antibody (manufacturer method; positive and indeterminate) | Negative Antibody (manufacturer method; positive and indeterminate) | Positive Antibody (modified method; positive and indeterminate) | Negative Antibody (modified method; positive and indeterminate) |
---|---|---|---|---|---|
No. | 50 | 24 | 26 | 13 | 37 |
Male/female | 13/37 | 7/17 | 6/20 | 2/11 | 9/28 |
Age, mean yrs | 57 | 57 | 56 | 57.5 | 56 |
Age at onset of RA, yrs | 49 | 49 | 48 | 48 | 49 |
History of smoking (+/total) | 10/43 | 5/19 | 5/24 | 1/13 | 9/37 |
Erosions (+/total) | 9/41 | 3/17 | 6/24 | 2/13 | 7/37 |
ESR, mean mm/h | 22 | 22 | 22 | 23.7 | 21.5 |
CRP, mean mg/dl | 6.8 | 6.9 | 6.8 | 7.5 | 6.6 |
Anti-CCP, mean U | 6 | 7.5 | 5.3 | 3.4 | 5.5 |
Therapy | |||||
Prednisone | 15 | 9 | 6 | 5 | 10 |
Plaquenil | 12 | 5 | 7 | 4 | 8 |
Methotrexate | 18 | 7 | 11 | 7 | 11 |
Anti-TNF | 17 | 6 | 11 | 4 | 13 |
None of these differences was statistically significant.